Last updated: February 25, 2026
What is the drug represented by NDC 82009-0132?
NDC 82009-0132 corresponds to Zepzelca (lurbinectedin), approved by the U.S. Food and Drug Administration (FDA) in June 2020. It is designated for treating metastatic small cell lung cancer (SCLC) that has progressed after platinum-based chemotherapy. The drug is marketed by PharmaMar and developed through a partnership with Jazz Pharmaceuticals.
Market Overview
Indication and Competitive Landscape
Zepzelca targets a niche market, specifically patients with relapsed small cell lung cancer. SCLC accounts for approximately 15% of lung cancers, with a 5-year survival rate below 7% for extensive-stage disease after standard chemotherapy.
Key Competitors
- Lurbinectedin (Zepzelca) has orphan drug designation for SCLC.
- Topotecan: The existing standard second-line therapy for relapsed SCLC.
- Cisplatin and Etoposide: Used as first-line therapy but less relevant post-progression.
Market Drivers
- Growing incidence of SCLC, approximately 30,000 new cases annually in the U.S. (SEER data).
- Limited treatment options after first-line chemotherapy.
- Increasing adoption of targeted and immune therapies in SCLC may influence the usage of Zepzelca.
Market Penetration Factors
- Regulatory status: Orphan drug designation facilitates development and market exclusivity.
- Pricing strategy: As an orphan drug, Zepzelca commands a premium price.
- Reimbursement: Coverage by Medicare and private insurers influences patient access.
Pricing and Revenue Projections
Current Price Point
- List price: Approximately $11,684 per three-dose cycle (per FDA labels).
- Actual reimbursement rates vary, with discounts likely reducing net price.
Revenue Estimates (2023–2028)
| Year |
Estimated Units Sold |
Revenue (USD million) |
Market Penetration (%) |
| 2023 |
1,200 courses |
$14 |
2% |
| 2024 |
2,400 courses |
$28 |
4% |
| 2025 |
4,000 courses |
$47 |
8% |
| 2026 |
6,500 courses |
$76 |
13% |
| 2027 |
9,000 courses |
$105 |
18% |
| 2028 |
12,000 courses |
$140 |
23% |
Assumptions:
- Steady increase in approval and adoption.
- No major market disruptions or emergence of superior therapies.
- Price remains stable, barring inflation or policy changes.
Market Challenges
- Limited patient pool due to rare indication.
- Competition from emerging therapies, including immunotherapy combinations.
- Price regulation pressures and insurer formulary restrictions.
Price Trajectory Outlook
- Short-term: Stable pricing at current levels, aligned with orphan drug status.
- Mid-term (2025–2028): Moderate price pressure expected due to competition and value-based pricing models.
- Potential for discounts or payer negotiations to slow price growth.
Key Factors Influencing Future Market and Pricing
- Regulatory approvals for expanded indications or combination options.
- New clinical trial data influencing treatment guidelines and physician adoption.
- Health policy reforms targeting drug prices and reimbursement frameworks.
- Competitive landscape evolutions, including biosimilars or generics, though unlikely due to patent protections.
Summary
NDC 82009-0132 (Zepzelca) operates in a small, targeted market with high unmet need, commanding premium pricing. Revenue depends heavily on market penetration driven by approval, reimbursement policies, and clinical efficacy perceptions. Price stability is expected through 2024, with modest declines possible thereafter due to competitive forces and policy shifts.
Key Takeaways
- Zepzelca’s current list price is approximately $11,684 per treatment cycle, targeting relapsed SCLC.
- Market size remains limited by the rarity of the disease, with estimated U.S. sales reaching $140 million by 2028.
- Future price changes will depend on clinical success, competitive innovations, and regulatory environment.
- Market growth prospects are moderate, with increased adoption contingent on clinical data and reimbursement policies.
- Disruption from emerging therapies could impact pricing and market share over the next five years.
FAQs
Q1: How might regulatory changes impact Zepzelca's pricing?
Changes promoting value-based pricing or drug price negotiations could lead to discounts, reducing revenue growth.
Q2: Is there potential for use in other cancer types?
No current approvals for off-label uses; future trials could expand indications, affecting market size.
Q3: How does competitors’ pricing compare?
Topotecan costs approximately $4,000-$6,000 per cycle, significantly lower; Zepzelca’s premium pricing reflects orphan status and targeted mechanism.
Q4: What reimbursement challenges exist?
Insurers may restrict coverage or negotiate discounts, impacting net revenue.
Q5: What is the outlook for patent protection?
Patent exclusivity extends until at least 2030, enabling price stability during this period.
References
- Food and Drug Administration (2020). Zepzelca (lurbinectedin) FDA approval letter.
- Surveillance, Epidemiology, and End Results Program (SEER). (2022). Lung and bronchus cancer stat facts.
- Jazz Pharmaceuticals (2021). Zepzelca prescribing information.
- IQVIA (2023). National Prescription Data.
- Statista (2022). Cost comparison of SCLC therapies.
